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Abstract
Background: The lack of a universal influenza vaccine is a global health problem. Interest is now focused on
structurally conserved protein domains capable of eliciting protection against a broad range of influenza virus
strains. The long alpha helix (LAH) is an attractive vaccine component since it is one of the most conserved
influenza hemagglutinin (HA) stalk regions. For an improved immune response, the LAH domain from H3N2 strain
has been incorporated into virus-like particles (VLPs) derived from hepatitis B virus core protein (HBc) using recently
developed tandem core technology.
Results: Fermentation conditions for recombinant HBc-LAH were established in yeast Pichia pastoris and a rapid
and efficient purification method for chimeric VLPs was developed to match the requirements for industrial
scale-up. Purified VLPs induced strong antibody responses against both group 1 and group 2 HA proteins in mice.
Conclusion: Our results indicate that the tandem core technology is a useful tool for incorporation of highly
hydrophobic LAH domain into HBc VLPs. Chimeric VLPs can be successfully produced in bioreactor using yeast
expression system. Immunologic data indicate that HBc VLPs carrying the LAH antigen represent a promising
universal influenza vaccine component.
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Background
Worldwide, influenza epidemics result in excessive
morbidity and the deaths of 250,000–500,000 people, an-
nually [1]. Seasonal epidemics and pandemics are caused
by group A influenza viruses, which are the main targets
of seasonal vaccines. Currently licensed influenza
vaccines are effective against homologous viruses,
however, these vaccines need to be reformulated for
every season on the basis of predictions of the upcoming
circulating subtypes. Prediction mismatches can impact
vaccine effectiveness, and have significant epidemio-
logical and economical consequences [2]. Moreover,
besides seasonal epidemics, influenza viruses can cause
occasional pandemics. Thus, development of a universal
influenza vaccine, which would protect against a broad
spectrum of influenza viruses, is warranted. Novel at-
tempts to construct such universal vaccines are generally
based on conserved antigens from influenza matrix
protein 2, as well as from the hemagglutinin (HA) stalk
domain [3]. However, these antigens are naturally weak
immunogens. Various strategies have been developed to
elicit more potent immune responses with broader
reactivity upon appropriate presentation to the host
immune system [1, 4].
Presentation on the surface of symmetric virus-like
particles (VLPs) stands out as one of the most efficient
approaches to improve immune responses to weak
antigens [5]. A number of attempts have been made to
* Correspondence: andris@biomed.lu.lv
1Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga LV-1067,
Latvia
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kazaks et al. BMC Biotechnology  (2017) 17:79 
DOI 10.1186/s12896-017-0396-8
construct broadly protective candidate vaccines based
on the conserved extracellular domain of matrix protein
2 (M2e) of influenza A viruses [6–9]. Although these
M2e-based VLP vaccine candidates have been success-
fully tested in animal models, further efficacy studies are
needed to demonstrate their protective potential in
humans [1]. In addition, many scientists now believe that
a universal and broad cross-protective influenza vaccine
may require additional components. One such potential
candidate is the structurally conserved 55 amino acid-long
alpha helix (LAH) of the HA stalk domain.
Here, we incorporated the LAH domain from H3N2
influenza virus into HBc VLPs using novel tandem core
technology based on the fusion of two HBc open reading
frames to produce a single polypeptide chain. This
strategy allows the insertion of large heterologous
sequences in one of the two major immunodominant
regions (MIR) located at the terminus of each spike,
without compromising VLP formation [10]. A chimeric
HBc-LAH gene was expressed in yeast Pichia pastoris.
This expression system is preferred to bacteria because
it avoids contamination with bacterial endotoxins.
Fermentation and purification conditions compatible
with industrial scale-up were established. The VLPs
obtained induced a strong and broadly cross-reactive
antibody response against several HA protein strains de-
rived from both group 1 and group 2 influenza A virus
subtypes in mice. These data indicate that tandem core
VLPs carrying the LAH antigen represent a promising
universal influenza vaccine component.
Methods
DNA constructions and yeast clone selection
A yeast codon optimized sequence encoding the tandem
core construct including lysine linkers in both MIRs was
designed and synthesized at GeneArt and cloned in the
pPICZC vector (Invitrogen) using BstBI and AgeI restric-
tion sites. Silent mutations were introduced up- and
downstream of the two MIRs to create unique restriction
sites (XbaI/NotI in Core 1 and EcoRI/NheI in Core 2). The
resulting plasmid pPICZC PHe7 K1,K1 (K1-K1, for short)
was used as a template for other MIR insertions. The
lysine-encluding linker in Core 1 was replaced by yeast-
optimized DNA sequence encoding the 55 amino acid
long influenza H3N2 virus (A/Hong Kong/1/1968, Acces-
sion № AAK51718) HA stalk domain (corresponding to
HA amino acids 420–474), using XbaI and NotI restric-
tion sites. Resulting pPICZC coHe(LAH3,K1) construct
(LAH3-HBc, for short) was linearized with PmeI to
transform P. pastoris KM71H electrocompetent cells via
electroporation. High copy number clones were selected
in 96 well plates with liquid YPD medium containing
0.2 mg/mL (first 48 h) and 2 mg/mL (following 48 h) of
zeocin. Cultures showing highest optical density (OD) at
A = 600 nm were selected and spread on YPD agar plates
in order to isolate single cell colonies. Selected clones
were analysed for insert copy number by quantitative real
time PCR based on the zeocin gene. The highest copy
clone was selected and used to generate a Research Cell
Bank.
Fermentation conditions for LAH3-HBc
For seed culture, 2 × 250 mL of buffered glycerol-
complex medium (BMGY; 1% (w/v) yeast extract, 2%
(w/v) peptone, 100 mM potassium phosphate buffer
pH 6.0, 1.34% (w/v) YNB, 0.0004% (w/v) biotin, and 1%
(v/v) glycerol) was inoculated with 1.8 mL of cell bank
suspension (BMGY culture in 30% (v/v) glycerol,
OD = 25.0) in 2 L baffled Nalgene® shakeflasks. After
16–18 h the OD of the flask was between 15 and 20 and
a 5% transfer volume was used to innoculate the
bioreactor.
Invitrogen’s fermentation protocol for Pichia pastoris
MutS strains was used to generate experimental material
in a 30 L BIOSTAT Cplus bioreactor (Sartorius). The re-
actor was filled with Basal Salts medium (26.7 mL/L
phosphoric acid (85%), 0.93 g/L CaSO4, 18.2 g/L K2SO4,
14.9 g/L MgSO4·7H2O, 4.13 g/L KOH, 40 g/L glycerol),
plus 4.35 mL PTM1 trace salts per litre of Basal Salts
media to achieve a total starting working volume of 10 L
post-inoculation. The PTM1 trace salts contained:
CuSO4·5H2O, 6.0 g/L; KI, 0.08 g/L; MnSO4·H2O, 3.0 g/
L; Na2MoO4·2H2O, 0.2 g/L; H3BO3, 0.02 g/L; ZnCl2,
20.0 g/L; FeCl3, 13.7 g/L; CoCl2 · 6H2O, 0.9 g/L; H2SO4,
5.0 mL/L; and biotin, 0.2 g/L.
The bioreactor was run in batch-mode after inoculation.
The dissolved oxygen tension (DOT) was maintained at
30% and was controlled in a sequence cascade by agitating
the impeller between 400 to 1000 rpm followed by oxygen
gas blending in ratio mode at a constant volumetric gas
flowrate of 0.51 vvm. The pH range was maintained
between 4.75–5.0 and pre-induction temperature at
30 ± 0.1 °C. A 20% drop in carbon evolution rate (CER)
and spike in DOT, indicating depletion of carbon source,
triggered the fed-batch induction phase. This was ob-
served 28.5 h after bioreactor inoculation.
This fed-batch induction phase was maintained for
48 h at a fixed flowrate of 50 mL/h. The induction
media itself is compromised of a 60:40 ratio of 50%
(v/v) glycerol and pure methanol repectively, plus
12 mL PTM1 salts per liter of induction media.
PPG2000 was used to prevent extensive foam forma-
tion throughout the fermentation. After 48 h of in-
duction the culture was cooled to 12 °C to minimize
proteolytic activity. Fermentation broth was harvested
at 3000 g, 20 min and 4 °C. The wet pellets were
weighed and stored at −20 °C.
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Purification and characterization of chimeric VLPs
Yeast cells were resuspended in lysis buffer (20 mM Tris
HCl, 100 mM NaCl, 0.1% Triton X-100, pH = 8.0) at a
proportion of 15% (w/v) and disrupted by French Press
(4 cycles, 10,000 psi). The soluble fraction was separated
by centrifugation (30 min, 18,000 g, +4 °C).
For purification of HBc K1-K1 VLPs, solid ammonium
sulfate was added until 35% of saturation by continious
stirring for 5 min following centrifugation (20 min,
18,000 g, +4 °C). The precipitate was dissolved in a min-
imal volume of 20 mM tris HCl pH = 8.0, subjected to
thermal treatment (30 min at 55 °C) and centrifuged
again. The supernatant was passed through an anion-
exchange HiPrep 16/10 DEAE Fast Flow column and the
flow-through fraction was collected. All chromatography
runs were monitored and controlled by an ÄKTA FPLC
chromatography device (GE Healthcare).
For purification of chimeric LAH3-HBc VLPs,
PEG6000 50% solution in 20 mM Tris HCl, pH = 8.0
(w/v) was added dropwise to the cell supernatant under
continious stirring until the final concentration reached
5% (w/v) and incubated 1 h at +4 °C. After centrifuga-
tion (20 min, 18,000 g, +4 °C) the precipitate was dis-
solved in a minimal volume of 20 mM tris HCl, 2 M
urea and loaded onto a size-exclusion Sepharose 4 FF
matrix (XK26/40 column, bed height 25 cm) in column
buffer A (20 mM Tris HCl, 100 mM NaCl, 1 M urea,
pH = 8.0) at V = 1 mL/min. 10 mL fractions were col-
lected and analyzed by native agarose gel, denaturing
PAGE, and electron microscopy. Selected fractions were
pooled and loaded onto anion-exchange Fractogel EMD
TMAE (M) column (Tricorn 10/50 column, 3.5 mL bed
volume) equilibrated with column buffer A. Column-
bound proteins were eluted with a linear gradient of 10
column volumes using column buffer A containing 1 M
NaCl. Fractions containing VLPs were dialized (10 kDa
MWCO membrane) against 100× excess of 20 mM Tris
HCl, 100 mM NaCl, pH = 8.0, with two buffer ex-
changes, for 48 h at +4 °C. Dialized material was pooled
and concentrated with Amicon 100 kDa MWCO filter
until it reached concentration of about 1 mg/mL. The
VLP preparation was aliquoted, slowly frozen at −70 °C
in a Mr. Frosty™ container and used for immunization of
mice.
Protein concentrations were estimated by the Bradford
assay. The purity of protein samples was analyzed by
SDS-PAGE according to standard protocols with a 4%
stacking and 15% separating polyacrylamide gel (PAAG).
To visualize protein bands, the gels were stained with
Coomassie Brilliant Blue G-250. Alternatively, separated
proteins were transferred onto nitrocellulose membrane
and detected by immunoblotting with the monoclonal
anti-HBc antibody and the anti-mouse IgG peroxidase
conjugate (DAKO). To assess nucleic acid content,
samples were subjected to native 1% agarose gel electro-
phoresis in TAE buffer (pH = 8.4) for approximately
0.5 h at 5 V/cm. Nucleic acids in the agarose gels were
visualized by ethidium bromide staining. A 1 kb DNA
ladder (Thermo Fischer Scientific) was used as a marker.
For transmission electron microscopy, the protein
samples (at c = 0.1–0.5 mg/mL) were adsorbed on
carbon-Formvar-coated copper grids and negatively
stained with 1% uranyl acetate aqueous solution. The
grids were examined with a JEM-1230 electron micro-
scope (JEOL Ltd., Tokyo, Japan) at 100 kV. Electron mi-
crographs were recorded digitally using a side-mounted
Morada camera (Olympus - Soft Imaging System GmbH,
Munster, Germany) with iTEM software (version 3.2,
Soft Imaging System GmbH).
Mouse immunizations
All mouse experiments were performed in accordance
with protocols approved by the Animal Welfare Structure
of the Minister of Agriculture, Viticulture and the Con-
sumer Protection of the Grand Duchy of Luxembourg
(Ref. LNSI-2014-02). Female BALB/c mice were pur-
chased from Harlan Laboratories, Inc. 8-week-old BALB/c
mice were immunized using a standard protocol including
3 intraperitoneal injections at 2 weeks interval with 30 μg
of chimeric LAH3-HBc VLPs for primary immunisation,
and with twice 15 μg for the second and third injection.
The antigen was dissolved in 100 μL phosphate buffered
saline adjuvanted with 100 μL MF59 (Addavax, Invivogen)
containing 20 μg CpG (OD2395 Vaccigrad, Invivogen)
totaling 200 μL per injected dose.
Enzyme-linked immunosorbent assay (ELISA)
Influenza-specific IgG in mouse serum was measured by
indirect ELISA using the following purified recombinant
group 1 and group 2 HA antigens at the given concen-
trations: A/Texas/36/1991 (Tex91) (H1, 1.5 μg/ml), A/
California/4/2009 (Cal09) (H1, 3.5 μg/ml), A/Japan/305/
57 (JP57) (H2, 1.25 μg/ml), A/Perth/16/2009 (Perth09)
(H3, 0.625 μg/ml), A/Swine/Ontario/01911–1/99
(Onta99) (H4, 1.25 μg/ml), A/Vietnam/1203/04 (VN04)
(H5, 1.25 μg/ml), A/Netherlands/219/2003 (Neth03)
(H7, 2.5 μg/ml), A/Hong Kong/1073/99 (HK99) (H9,
1.25 μg/ml), A/Jiangxi-Donghu/346/2013 (JX13) (H10,
2.5 μg/ml), A/mallard /Alberta/294/1977 (Alb77) (H11,
1.25 μg/ml), A/mallard/Astrakhan/263/1982 (Astrak82)
(H14, 1 μg/ml), and A/duck/AUS/341/1983 (AUS83)
(H15, 2 μg/ml) all purchased from Sino Biological Inc.
Subsaturating coating concentrations were determined
with a serum of a mouse sublethally challenged either
with pH1N1 (group 1 HA) or H3N2 (group 2 HA) or
with specific monoclonal antibodies against HA H1N1,
HA H3N2, HA H5N1, HA H7N9 and HA H9N2 from
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the same supplier, after coating ELISA plates with three-
fold dilution series of each antigen.
Wells of 384-well microtiter plates (Greiner) were
coated overnight at 4 °C with 20 μL/well of 3.5 μg/mL
purified HA proteins in carbonate buffer (100 mM,
pH = 9.6) or with carbonate buffer alone as a
background control. Irrelevant antigens (Cytomegalo-
virus grade 2 antigen, 2 μg/ml; purified EBV capsid
protein, 30 ng/ml; Toxoplasma gondii antigen, 2 μg/ml;
Microbix, Mississauga, Canada) served as negative anti-
gen controls. Reactivity against “empty” HBc VLPs
(20 μl per well of 2 μg/ml) was used as positive control.
All subsequent steps were performed at room
temperature. Wells were washed sequentially in washing
buffer (Tris HCl containing 1% Tween 20) and blocked
for 2 h with 1% BSA in Tris buffer. After washing, sera
(starting with a 100-fold dilution) were added, incubated
for 90 min, and washed. Alkaline phosphatase conjugated
goat anti-mouse IgG (1/750 dilution, ImTec Diagnostics)
was added for 90 min, washed and developed using 2-
amino-2-methyl-1-propanol. Absorbance was measured at
405 nm (Spectromax Plus, Sopachem) after 60 min
incubation.
Results and discussion
Modification of the HBc gene
The insertion of heterologous sequences into viral struc-
tural genes generates chimeric VLPs that can be used as
stable nanocontainers for diagnostics, vaccination and
gene transfer purposes [11, 12]. The successful assembly
of chimeras is dependent on the nature of the insert as
well as its position within the carrier gene. For HBc, the
MIR is generally considered as the most promising
insertion site of the HBc molecule due to its surface
exposure and high insertion capacity [13]. Recently, a
number of approaches have been developed for MIR-
insertion and the presentation of “difficult” protein se-
quences including large, charged and/or hydrophobic
domains, T-cell epitopes, and cell-receptor ligands.
These strategies include the SplitCore [14], the use of a
non-covalent “binding-tag” peptide [15], and the tandem
core technology. The latter is based on a genetically
fused HBc dimer that can assemble in correctly folded
HBc VLPs [16] while accomodating large heterologous
sequences [10].
Previously, we have demonstrated that the yeast P.
pastoris system is well suited for high-level of synthesis
and purification of wild-type HBc VLPs expressed from
a cloned HBc monomer gene [17]. The current study is
based on so called hetero-tandem core, where a C-
terminally truncated HBc monomer gene (Core 1, 149
aa) was genetically fused via a GGSx7 linker with a full-
length HBc monomer gene (Core 2, 185 aa) to form a
covalently linked dimer. To further explore the potential
of this HBc carrier, we introduced into each MIR two
short sequences encoding a lysine codon flanked on
both sides by flexible glycine linkers (Fig. 1a). Such
surface-exposed lysine residues can be efficiently used
for chemical coupling of peptides containing reactive SH
groups provided by free cysteine residues [18]. The
resulting construct K1-K1 was transformed in yeast P.
pastoris. The selected clone containing multiple
a
b c
Fig. 1 a Design of the HBc K1-K1 construct. Amino acid sequences of inserted lysine linkers are showed in upper part. Below, introduced unique
restriction sites at both ends of the linkers (XbaI/NotI in Core1 and EcoRI/NheI in Core2) are underlined. Purified K1-K1 VLPs were characterized by
Coomassie-stained PAAG (b) and electron microscopy (c)
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ac
b
Fig. 3 Extraction of the LAH3-HBc protein from yeast cell lysates. a Coomassie-stained PAAG illustrating individual purification steps. Target
protein corresponding band is marked by arrowhead. Sup, protein content in cell supernatant; PEG, protein precipitate loaded onto SEC column;
1–5, SEC fractions corresponding to column profile (b). c Electron microscopy analysis of VLP region from SEC elution
a
b c
Fig. 2 Construction and expression of the recombinant LAH3-HBc gene. Design (a) and cartoon (b) of the LAH3-HBc dimer. Individual HBc
monomers are coloured in green and orange. First MIR contains the LAH domain (represented as random pink spheres) while the second MIR
contains lysine linker (blue spheres). The model was created using PyMOL version 1.7rc1. The tandem core dimer was based on the structure from
PDB-1QGT, with the linker added in black. c LAH3-HBc fermentation profile. Dissolved oxygen tension (DOT) was maintained above 30% through
agitation control (N) between 400 to 1000 rpm. Biomass was monitored post-induction by wet cell weight (WCW) analysis
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integrated expression units ensured high-level synthesis
of the soluble target protein and was easily purified from
yeast cells as correctly formed HBc VLPs (Fig. 1b-c).
Our early attempts to incorporate a highly hydropho-
bic LAH domain from influenza HA stalk into the MIR
of monomeric HBc gene in E. coli resulted in insoluble
products (data not shown). This is in line with previous
observations [19] and indicated that specific approaches
like tandem core technology might be necessary to im-
prove solubility and achieve formation of VLPs incorpor-
ating LAH. Since very promising results were obtained
with the hetero-tandem HBc based K1-K1 construct, we
inserted the LAH-encoding sequence into the MIR of
the truncated HBc gene (Core 1) while the MIR of
the full-length HBc (Core 2) remained unchanged
(Fig. 2a-b). In order to exploit “endotoxin-free” cells
with the potential for further industrial scale-up pos-
sibilities we transferred the chimeric tandem core
gene into the yeast P. pastoris vector system resulting
in LAH3-HBc construct.
Expression of LAH3-HBc construct in yeast
Recently, a number of novel influenza monoclonal anti-
bodies have been identified against the stalk domain of
the HA relatively conserved across most HA subtypes.
These antibodies are able to broadly neutralize a wide
spectrum of influenza virus strains and subtypes [20].
The LAH domain is a small alpha-helical portion of the
stalk domain which contains a well-characterised neu-
tralizing epitope for mAb 12D1 [21]. However, when out
of structural context LAH does not generate neutralizing
antibodies. Nevertheless, several studies from different
research groups suggest that the LAH domain is a
promising vaccine component. The current hypothesis
for the mechanism of action involves non-neutralising
antibody mediated cellular immune processes such as
antibody dependent cellular cytotoxicity and comple-
ment dependent cytotoxicity [22] which are difficult to
measure in mice. The synthetic LAH peptide from
H3N2 virus coupled to carrier protein keyhole limpet
hemocyanin induced in mice not only strong protection
a b c
d
e
Fig. 4 Final purification (a) and characterization (b-e) of LAH3-HBc VLPs. a Fractogel TMAE chromatography profile. VLP and free nucleic acid (NA)
peaks are indicated. b Coomassie-stained PAAG of final product after dialysis and concentration. 1, 2 and 4 μl of protein are loaded per track.
c Western blotting of final product. Lane 1, negative control; lane 2, K1-K1 VLPs; lane 3, LAH3-HBc VLPs. Full-length protein and product related
bands are marked by arrowhead and asterix, respectively. d Nucleic acid content of final product in native agarose gel. Visible is only VLP-
associated NA band (indicated by arrowhead). e Quality of LAH3-HBc VLPs verified by electron microscopy
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against homologous virus but also partial protection
against distinct virus strains [23]. Similarly, the LAH re-
gion of H7N9 influenza virus was inserted into the HBc
gene and the resulting chimeric HBc-LAH VLPs induced
strong protection against homologous and heterologous
virus strains in mice [24]. The latter study, however, re-
quired a complex renaturation procedure extracting
chimeric protein from insoluble aggregates in E. coli,
a process that would be costly and difficult to scale-
up for industrial manufacturing. In addition, this
approach is also compromised by the presence of
bacterial endotoxins.
To avoid these problems we aimed to produce LAH3-
HBc VLPs in yeast cells. Yeast P. pastoris is well-adapted
for large-scale fermentation and is a useful system for
the expression of milligram-to-gram quantities of pro-
teins for both basic laboratory research and industrial
manufacture [25, 26]. Clones with multiply integrated
expression cassettes were obtained in order to ensure
maximal synthesis of the target protein in line with
previous reports [27, 28]. Here, the clone with 50 ± 2
integrated expression units was selected for further
experiments (see Additional file 1).
Fermentation conditions were established to maximise
product yield in the soluble fraction, as determined by
HBc-specific Western blots and its assembly into a
VLPs, as determined by electron microscopy. It should
be noted that several induction stategies were evalutated,
including the standard methanol induction method for
MutS strains. We observed that for the K1-K1 construct,
the methanol only induction method yielded the most
VLP material, yet when this same method was used for
the LAH3-HBc construct, little or no product was ob-
served (data not shown). The different constructs did
not appear to effect biomass as both seemed to grow
well. We therefore sought to examine different induction
methods, including various flowrates and glycerol:-
methanol ratios in the induction feed. Eventually we dis-
covered that the 60:40 ratio of 50% glycerol:methanol
over 48 h of induction provided the best yield for
Fig. 5 Reactivity of mouse sera with recombinant group 2 HA proteins (H3, H4, H7, H10, H14 and H15). Mice were immunized with LAH3-HBc
VLPs or adjuvant alone (“Mock”). The panels show the mean and standard deviation of the optical density at 405 nm of the sera of 16 mice per
group and are representative of two distinct experiments
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LAH3-HBc. Based on the off-gas data (not shown), in all
cases the cells seemed metabolically actively and grew
well, however product expression was construct
dependent – possibly indicating that the complexity and
self-assembly of different VLP constructs are not intrin-
sically linked to cell metabolism during fermentation.
Wet cell weight at the end of fermentation reached
178 g/L. The overall fermentation process is presented
schematically in Fig. 2c.
Purification and characterization of chimeric LAH3-HBc
VLPs
Efficient and selective concentration of the protein of
interest from crude cell lysates is often a critical step de-
termining overall success of the whole purification
process. For HBc VLPs, ammonium sulfate precipitation
has been used with good results ([17] and references
herein). However, in this particular case it resulted in
co-precipitation of the VLPs with other host cell proteins
which were difficult to remove in the subsequent purifi-
cation steps (data not shown). In contrast, addition of
PEG led to selective enrichment of the target protein
with a calculated MW of 48.2 kDa from cell supernatant
(Fig. 3a). Since the LAH domain is highly hydrophobic,
addition of urea was necessary to complete solubilization
of the PEG precipitate and reduce aggregation caused by
hydrophobic interactions. Next, the protein mixture was
loaded onto a size-exclusion chromatography (SEC) col-
umn containing Sepharose 4 FF, a matrix developed for
industrial processing of large molecules and virus parti-
cles at high flow rates and moderate pressures. We did
not exceed the bed height of 25 cm in line with manu-
facturer’s recommendations. A typical chromatography
profile is shown in Fig. 3b. The aggregate peak appears
first and this also contains a minor proportion of the tar-
get protein. The peak fractions are cloudy, contain a
large amount of contaminating proteins and are not use-
ful for the further purification of LAH3-HBc VLPs (data
not shown). The next part of the profile is the so called
“flat” region which theoretically corresponds to migra-
tion of VLP-size proteins. Indeed, SDS-PAGE analysis
revealed the presence of LAH3-HBc sized protein in
Fig. 6 Reactivity of mouse sera with recombinant group 1 HA proteins (seasonal HA1, pandemic H1, H2, H5, H9 and H11). The mouse sera were
the same as for Fig. 5. The panels show the mean and standard deviation of the optical density at 405 nm of the sera of 16 mice per group and
are representative of two distinct experiments
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these fractions (Fig. 3a) while electron microscopy con-
firmed the presence of correctly formed VLPs (Fig. 3c).
However, the major component of these fractions com-
prised misassembled but soluble protein material.
For the second stage of the purification we aimed to
maximally reduce the content of (i) contaminating pro-
teins, (ii) misassembled LAH3-HBc aggregates and (iii)
VLP non-associated nucleic acid. Ideally, this should be
achieved by a single chromatography step. Our attempts
to use either Sephacryl S1000 SEC, or differential pre-
cipitation of fractions by ammonium sulfate/PEG gener-
ally failed due to low yield and/or poor reproducibility
(data not shown). We then subjected the protein solu-
tion to several anion exchangers as a relatively cheap, ro-
bust material capable of withstanding harsh cleaning-in-
place conditions. The strong anion exchanger Sepharose
Q HP matrix ensured good separation of nucleic acid
but led to disassembly of VLPs (data not shown). Experi-
ments were continued with Fractogel DEAE and TMAE
matrices representing weak and strong anion ex-
changers, respectively. Both of them resulted in signifi-
cant enrichment of correctly folded VLPs in column-
eluted material, however, only the TMAE matrix ensured
nearly complete separation of VLPs from VLP-free nu-
cleic acid (Fig. 4a). After dialysis and concentration the
final product was analyzed for its purity, nucleic acid
content and VLP quality (Fig. 4b-e). The final product
reached at least 90% of homogeneity but appeared as
two bands in PAAG (Fig. 4b). However, both bands
reacted in Western blotting with anti-HBc antibody
(Fig. 4c) indicating that the lower one is not a contamin-
ant but a product related band. Since this protein was
a b
c
Fig. 7 Reactivity of individual mouse sera (OD405 of a 1:300 serum dilution from Figs. 5 and 6) with homologous group 2 (a) and heterologous
group 1 HA antigens (b) after immunization with LAH3-HBc VLPs (N = 16) or after mock (N = 16) immunization. c shows the same aggregated
results by reactivity with group 1 or group 2 antigens. The threshold for positivity (dotted line) is defined by comparison to the mock i.e. adjuvant
only immunized mice
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not removed by SEC we assume it is incorporated into
the VLPs.
After the first SEC column, the total protein content
of VLP region was calculated as ~4 mg per 5 g of wet
cells. These fractions, however, contained a mixture of
proteins with an indeterminate percentage of correctly
folded VLPs. In contrast, after elution from the anion
exchange column more than 80% of material was in the
form of VLPs but the yield in terms of total protein was
decreased to ~0.5 mg. This result is in line with the as-
sumption that correctly assembled VLPs comprise about
10% of total protein after SEC separation. These data
were reproduced with consistency in at least three inde-
pendent purification processes.
To summarize, in conditions described a final yield of
LAH3-HBc VLPs could be estimated as 17–18 mg/L.
For comparison, outcome of K1-K1 VLPs is typically
~0.8 mg per 1 g of cells, with its biomass after fermenta-
tion 260–270 g/L, which gives final yield 208–216 mg/L.
Therefore incorporation of LAH domain decreases out-
come of VLPs by more than the order of magnitude.
This is still acceptable for industrial manufacturing, al-
though further optimisation may increase the outcome
and lower the process cost.
Induction of broadly reactive antibodies by immunization
To elicit antibodies against the influenza virus, BALB/c
mice were immunized 3 times with chimeric LAH3-HBc
VLPs at two weeks intervals. 10 days after the third
immunization all immunized animals showed high titers
of antibodies against the homologous group 2 HA pro-
teins, including H3, H4, H7, H10, H14, and H15, while
the mock group showed no reactivity with the antisera.
Only H10 gave a weaker reaction (Fig. 5). In addition,
the VLP-induced antisera cross-reacted significantly with
the heterologous group 1 HA proteins, including H1,
H2, H5, H9, and H11, but the reactivity was significantly
weaker (P < 0,0001) than with group 2 HA (Figs. 6 and
7). The lowest reactivity was with H2 and H5 antigens.
Fig. 7 shows that all mice reacted at a serum dilution of
1:300 with all group 2 HA species. Those with the low-
est reactivity to the group 2 HA antigen were also the
same one or two mice which had consistantly low levels
of reactivity with group 1 HA. Thus chimeric LAH3-HBc
VLPs induced broadly reactive anti-influenza serum
against both group 1 and 2 HA proteins. While all animals
reacted with the “empty” K1-K1 HBc VLPs, none of them
showed any reactivity (OD < 0,1) with the irrelevant anti-
gens (EBV, CMV, Toxoplasma, see Additional file 2).
Conclusion
We have demonstrated that the tandem core technology
is a useful tool for incorporation of “difficult” sequences
like the hydrophobic LAH domain into HBc VLPs while
cloning into the classical, unmodified monomeric HBc
gene results in insoluble products. The chimeric LAH3-
HBc VLPs were successfully produced in a bioreactor
using yeast P. pastoris expression system. The relatively
low production yield was partially compensated by an ef-
ficient purification protocol of the chimeric VLPs. The
LAH3-HBc VLPs induced broadly reactive antibodies
against both group 1 and 2 HA proteins, the hallmark of
a universal vaccine against influenza A viruses.
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method used. (PPTX 91 kb)
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